Bruno Julianne 4

4 · CRISPR Therapeutics AG · Filed Mar 12, 2025

Form 4

Period: 2025-03-10

Chief Operating Officer

Transactions

Exercise/Conversion
Common Shares
2025-03-10+2,399→ 9,461 total
Sale
Common Shares
2025-03-12$43.32/sh−190$8,231→ 8,508 total
Exercise/Conversion
Common Shares
2025-03-11+435→ 8,698 total
Exercise/Conversion
Restricted Stock Units
2025-03-10−2,399→ 4,796 total
→ Common Shares (2,399 underlying)
Sale
Common Shares
2025-03-11$42.42/sh−1,198$50,819→ 8,263 total
Exercise/Conversion
Restricted Stock Units
2025-03-11−435→ 0 total
→ Common Shares (435 underlying)

Holdings

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
[F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
[F3]This restricted stock unit award was granted on March 10, 2023 with respect to 9,593 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
[F4]This restricted stock unit award was granted on March 11, 2021 with respect to 1,740 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

Documents

1 file